Advancements, challenges and future of 3D Bioprinting – Interview with Tomi Kalpio from Brinter
Fortschritte, Herausforderungen und Zukunft von 3D Bioprinting – Interview mit Tomi Kalpio von Brinter
Finland-based AM Technologies by Brinter Ltd specializes in Additive Manufacturing solutions for the biotech and pharmaceutical industries. Leveraging advanced 3D bioprinting technologies, it addresses the complex challenges faced by these sectors, offering innovative and efficient solutions for both research and clinical applications. In an interview with 3Druck.com, AM Technologies by Brinter CEO and co-founder of Brinter Inc Tomi Kalpio provides valuable insights into the evolving 3D bioprinting industry.
“3D bioprinting is advancing tissue engineering and regenerative medicine by enabling the precise creation of complex, tissue-like structures. Precision and speed are key aspects that are rapidly developing by combining different additive manufacturing methods into one platform. This allows the fabrication of customized tissue grafts, even using a patient’s own cells, improving both personalized treatments and medicines. The same technology platforms also improve drug testing with accurate, human-like tissue models, aiding faster development. In addition, bioprinting supports the regeneration of damaged tissues, such as cartilage and skin, and the development of functional organoids for disease research. There is also great potential in both hard and soft tissue engineering for human spare parts (from implants to bioimplants to organs).”
For additional information:
Tomi Kalpio
CEO of Brinter AM Technologies Ltd and co-founder of Brinter Inc
About : Brinter AM Technologies Oy
